Close Menu

Memorial Sloan-Kettering

Researchers found that ADAR works by stabilizing the FAK gene, which is one of a subset involved in cell migration pathways.

Not Yet for Watson

Stat News reports that IBM's Watson for Oncology isn't yet living up to its promise.

Researchers from MSKCC reported today in JAMA that of 1,040 cancer patients referred for germline mutation testing, 18 percent had actionable variants.

This small, for-profit Dutch company has been a driving force behind freeing cBioPortal from Memorial Sloan Kettering, as well as continued development of the software.

Though researchers highlighted their goal of using the method to move toward a test to detect early cancers, their current data speaks only to the method's performance in late-stage cancer patients.

Philips has teamed with Illumina and Intermountain Healthcare's Navican on informatics for precision medicine and signed a genome analytics deal with Memorial Sloan Kettering Cancer Center.

The company hopes to raise funding this summer and has been conducting pilots with NewYork-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center.

In Nature this week: variability in iPSCs, the silver birch, and more.

More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial. 

The amount of cancer data being generated is driving researchers to develop artificial intelligence and deep machine-learning methods to help them keep up.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.